



## ASX ANNOUNCEMENT

### Special General Meeting presentation

**For Immediate Release:**

**7 April 2020**

**Sydney, Australia** – Simavita Limited (ASX: SVA) is pleased to release the attached slide show presentation which will be delivered by its Chairman, Mr Michael Spooner, at the Company’s Special General Meeting to be held at 11.00 am this morning at the offices of K&L Gates, Level 31, 1 O’Connell Street, Sydney, New South Wales, Australia.

Due to the ongoing global COVID-19 pandemic and the current requirements for social distancing and restrictions on public gatherings, the Special General Meeting will be conducted via webcast and CDI holders are strongly advised not to attend the offices of K&L Gates in Sydney and to only attend by webcast.

The Special Meeting will be streamed live via the following link:

Webcast link: <https://webcasting.boardroom.media/broadcast/5e796c8c9c34da0e14bb7e10>

The webcast will also be available on the Simavita website from 5.00pm Australian Eastern Standard Time via the same link.

Questions may be submitted during the webcast via the webcast portal chat function.

#### Further information

For further information, please visit the Company’s profile on SEDAR ([www.sedar.com](http://www.sedar.com)) or the Company’s website ([www.simavita.com](http://www.simavita.com)) or contact the persons listed below.

Ms Peta Jurd  
Chief Commercial Officer

E: [pjurd@simavita.com](mailto:pjurd@simavita.com)  
T: +61 421 466 653  
W: Investor Centre: [Click here](#)

*This ASX announcement was approved and authorised for release by Peta Jurd, Company Secretary of Simavita Limited.*

#### About Simavita

Simavita (ASX: SVA) is a MedTech Company focused on the development of smart, wearable and disposable platform technologies for the health care market.

Our key platform Smartz™ is a highly disruptive technology focused on transforming a traditional “dumb” diaper into a smart device to help parents and carers of both infants and adults.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. [www.simavita.com](http://www.simavita.com)

Simavita

# Managing our business in challenging times

Special General Meeting, 7 April 2020

# FORWARD LOOKING STATEMENTS

This presentation may contain “forward-looking information” within the meaning of Canadian securities laws (“forward-looking information”). This forward-looking information is given as of the date of this document.

Forward-looking information relates to future events or future performance and reflects Simavita management’s expectations or beliefs regarding future events. Assumptions upon which such forward-looking information is based include that Simavita will be able to successfully execute on its business plans. Many of these assumptions are based on factors and events that are not within the control of Simavita and there is no assurance they will prove to be correct. In certain cases, forward-looking information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or information that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology. By its very nature, forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Simavita to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors include, among others, risks related to actual results of current business activities; changes in business plans and strategy as plans continue to be refined; other risks of the medical devices and technology industry; delays in obtaining governmental approvals or financing or in the completion of development activities; as well as those factors detailed from time to time in Simavita’s interim and annual financial statements and management’s discussion and analysis of those statements. Although Simavita has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Simavita provides no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information.

We're well positioned to move forward



## We're ready:

- App and cloud-based systems are ready
- Product ready including smart diapers & PODs
- Extensive testing completed
- Manufacturers in our major markets:
- Proven manufacturability (adult & infant)
- Manufacturers commenced product testing

## Corporate:

- Adequately funded (\$2,920,000 raised 26 Feb)
- Assets in place to commence roll-out



Covid-19 has slowed clinical progress



Planned Clinical progress has slowed progress:

- Sites for international clinical roll out selected
- Training, equipment and software are ready
- International resources available to participate
- In the mean-time we continue to work with users



## Our commitment to the future



We're ready to run, post Covid-19:

- Board and Management committed
- Adequately funded to achieve milestones
- Tight .. Tight ... cost control
- All staff working remotely and extremely effectively
- Focus on materially advancing product functionality
- Continuing and significant discussion with partners



# Thank You.

